GeneHealth - Your precision medicine

Dilated Cardiomyopathy 1bb

Disease Details

Family Health Simplified

Buy Membership

Description: Dilated cardiomyopathy (DCM) is a condition where the heart becomes weakened and enlarged, unable to pump blood efficiently.

One-sentence description: Dilated cardiomyopathy is a disease characterized by an enlarged and weakened heart muscle that diminishes the heart's ability to pump blood effectively.
Type: Dilated cardiomyopathy 1BB (DCM 1BB) is an inherited heart condition characterized by the dilation and impaired contraction of the left ventricle. The type of genetic transmission for DCM 1BB is autosomal dominant.
Signs And Symptoms: Dilated cardiomyopathy (DCM) exhibits a range of signs and symptoms, which can include:

1. Shortness of breath (dyspnea), especially during exertion or when lying down
2. Fatigue and weakness
3. Swelling in the legs, ankles, and feet (edema)
4. Swelling of the abdomen (ascites)
5. Persistent cough or wheezing, sometimes with frothy pink mucus
6. Reduced ability to exercise
7. Rapid or irregular heartbeats (palpitations)
8. Chest pain or discomfort
9. Dizziness, lightheadedness, or fainting (syncope)

These symptoms result from the heart's decreased ability to pump blood effectively, leading to a buildup of fluid and insufficient oxygen supply to the body's tissues.
Prognosis: Dilated cardiomyopathy (DCM) type 1BB is a genetic condition characterized by the dilation and impaired contraction of the left or both ventricles of the heart, leading to reduced cardiac output. The prognosis of DCM can vary widely depending on factors such as the underlying cause, severity at diagnosis, response to treatment, and presence of comorbidities. Generally, the prognosis is more favorable with early diagnosis and appropriate management, which may include medications, lifestyle changes, and sometimes surgical interventions like implantable devices. Without treatment, the condition can progress to heart failure and other serious complications.
Onset: Dilated cardiomyopathy 1BB is associated with an onset generally in adulthood. This genetic condition affects the heart muscle, leading to its dilation and impaired ability to pump blood effectively. The term "nan" appears to be a placeholder or an error in the provided context. For further details, more specific questions may be required.
Prevalence: Dilated cardiomyopathy typically affects around 1 in 2,500 individuals. For the specific subtype "dilated cardiomyopathy 1BB," there is limited data on its exact prevalence, but it is considered part of the broader category of genetic dilated cardiomyopathies.
Epidemiology: For dilated cardiomyopathy (DCM1BB), a specific genetic subtype of dilated cardiomyopathy:

**Epidemiology:**
Dilated cardiomyopathy (DCM), including genetic subtypes like DCM1BB, affects approximately 1 in 250 to 1 in 500 individuals globally. It is a significant cause of heart failure and the most common reason for heart transplantation. DCM can manifest at any age but is most often diagnosed in adults between 20 and 60 years old. Family history plays a crucial role, with 20-50% of cases being familial.

**Natural History and Prognosis:**
Patients with DCM1BB can present with varying degrees of left ventricular dilation and systolic dysfunction, leading to heart failure, arrhythmias, and an increased risk of sudden cardiac death. The prognosis depends on disease severity, response to treatment, and the presence of complications like heart failure or arrhythmias.
Intractability: Dilated cardiomyopathy (DCM) can be a challenging condition to manage, but it is not necessarily intractable. Treatment options such as medications, lifestyle modifications, and sometimes surgical interventions like the implantation of a pacemaker or a heart transplant can help manage the symptoms and improve quality of life. Each patient's prognosis can vary depending on the severity of the condition and how well it responds to treatment.
Disease Severity: Dilated Cardiomyopathy 1BB refers to a form of dilated cardiomyopathy that is typically genetic. Disease severity can vary widely among individuals. Some people may experience mild symptoms while others may suffer from severe heart failure. It can lead to complications such as arrhythmias, thromboembolic events, and in advanced cases, could require a heart transplant. Regular monitoring and medical management are crucial to mitigate its progression and impact on quality of life.
Healthcare Professionals: Disease Ontology ID - DOID:0110458
Pathophysiology: Dilated Cardiomyopathy 1BB (DCM1BB) is a genetic form of dilated cardiomyopathy. The pathophysiology involves the dilation and impaired contraction of the left ventricle, leading to a decrease in cardiac output. This condition can result from mutations in genes encoding proteins critical for the structure and function of cardiac muscle cells, leading to weakened myocardial fibers, disrupted cellular integrity, and impaired contractile function. Over time, this can cause heart failure and arrhythmias due to the progressive nature of the ventricular dilation and systolic dysfunction.
Carrier Status: For dilated cardiomyopathy 1BB (DCM1BB), the concept of carrier status may not be directly applicable as it typically involves dominant inheritance patterns or complex genetic contributions. If there's a specific mutation or gene associated (e.g., a known gene mutation with incomplete penetrance), a carrier would technically be an individual who possesses one copy of the mutation. "NaN" (not a number) seems out of context here and may not be relevant.

If you have more detailed information or a specific context in which "carrier status" and "NaN" are used, please provide it for a more precise explanation.
Mechanism: Dilated cardiomyopathy 1BB (DCM1BB) is a specific subtype of dilated cardiomyopathy, often linked to genetic mutations. The primary mechanism involves the enlargement and weakening of the heart's ventricles, inhibiting efficient blood pumping, which can lead to heart failure.

**Molecular Mechanisms:**

1. **Genetic Mutations:** DCM1BB is often caused by mutations in genes that encode for proteins essential in maintaining cardiac muscle structure and function.
2. **Sarcomere Dysfunction:** Mutations may occur in genes coding for sarcomere proteins (e.g., titin, actin, myosin). These proteins are crucial for muscle contraction, and their disruption leads to impaired cardiac contractility and ventricular dilation.
3. **Cytoskeletal Abnormalities:** Mutations in cytoskeletal proteins such as dystrophin can lead to structural instability of cardiac cells, causing cell death and fibrosis.
4. **Energy Metabolism Impairment:** Genetic defects in mitochondrial function can lead to insufficient energy production in cardiac cells, further contributing to heart muscle weakening.
5. **Ion Channel Dysfunction:** Mutations affecting ion channels can disrupt electrical signaling in the heart, adversely affecting cardiac contractility and rhythm.

These molecular changes result in progressive dilatation and systolic dysfunction of the ventricles, which characterizes DCM1BB.
Treatment: Dilated cardiomyopathy (DCM) is a condition characterized by the heart's diminished ability to pump blood due to an enlarged and weakened left ventricle. While there’s no cure for DCM, treatments focus on managing symptoms and preventing complications. Here are common treatment approaches:

1. **Medications:**
- **ACE Inhibitors or ARBs:** Help relax blood vessels and reduce the workload on the heart.
- **Beta-Blockers:** Slow the heart rate and lower blood pressure.
- **Diuretics:** Reduce fluid buildup.
- **Aldosterone Antagonists:** Help remove excess sodium and fluid.

2. **Device Therapy:**
- **Implantable Cardioverter-Defibrillators (ICDs):** Prevent sudden cardiac death.
- **Cardiac Resynchronization Therapy (CRT):** Improves the heart's efficiency.

3. **Lifestyle Changes:**
- **Diet:** Low-salt, low-fat diet.
- **Exercise:** Regular physical activity adapted to individual capacity.
- **Weight Management:** Maintaining a healthy weight.

4. **Surgery:**
- **Heart Transplant:** In severe cases where other treatments fail.
- **Ventricular Assist Devices (VADs):** Helps the heart pump blood.

Regular monitoring and follow-ups with a cardiologist are crucial for managing the condition effectively.
Compassionate Use Treatment: For Dilated Cardiomyopathy (DCM), particularly genetic subtypes like DCM1BB, compassionate use treatments and off-label or experimental treatments are considered when standard therapies are ineffective or unavailable. These treatments might include:

1. **Gene Therapy**: Experimental gene therapies targeting specific mutations causing DCM1BB are being researched. These aim to correct the underlying genetic defect.

2. **Stem Cell Therapy**: This is an area of ongoing research. Some studies suggest that injecting stem cells into the heart may help regenerate damaged heart tissue.

3. **Heartware and Bi-Ventricular Assist Devices**: These mechanical devices support heart function and blood flow, often used while awaiting a heart transplant.

4. **Pharmacologic Agents**: Some off-label use of drugs such as:
- **Sacubitril/valsartan (Entresto)**: Typically indicated for heart failure, it might be considered for DCM.
- **Ivabradine (Corlanor)**: Used primarily for heart failure, it may help reduce symptoms in DCM patients.
- **SGLT2 inhibitors (e.g., dapagliflozin)**: Primarily for diabetes, these have shown benefit in heart failure.

5. **Immunosuppressive Therapy**: In cases where an immune-mediated process is suspected, off-label use of immunosuppressive drugs like corticosteroids may be considered.

Access to these treatments typically requires participation in clinical trials or specific regulatory approvals under compassionate use programs.
Lifestyle Recommendations: Lifestyle recommendations for dilated cardiomyopathy (DCM) include:

1. **Dietary Modifications**: Adopt a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins. Limit salt intake to manage blood pressure and fluid retention.

2. **Regular Exercise**: Engage in moderate aerobic activities, such as walking or cycling, as tolerated. Consult with a healthcare provider for a tailored exercise plan.

3. **Alcohol and Tobacco**: Avoid alcohol and quit smoking, as both can exacerbate heart problems.

4. **Medications Compliance**: Take prescribed medications precisely as directed by your healthcare provider to manage symptoms and prevent complications.

5. **Weight Management**: Maintain a healthy weight to reduce the heart's workload.

6. **Monitor Symptoms**: Regularly monitor for symptoms such as swelling, shortness of breath, and sudden weight gain. Contact a healthcare provider if these occur.

7. **Regular Check-ups**: Attend all medical appointments and follow up with healthcare providers to monitor heart function and adjust treatments as necessary.

8. **Stress Management**: Implement stress-reducing techniques such as meditation, yoga, or breathing exercises.

9. **Avoid Large Meals**: Consume smaller, more frequent meals to ease cardiac workload.

10. **Stay Hydrated**: Ensure adequate fluid intake but monitor it closely if advised by a healthcare provider, especially if there are concerns about fluid retention.
Medication: For dilated cardiomyopathy, treatment typically focuses on managing symptoms and improving heart function. Medications commonly used include:

1. **ACE inhibitors** (e.g., enalapril, lisinopril): to help relax blood vessels and lower blood pressure.
2. **Beta-blockers** (e.g., carvedilol, metoprolol): to reduce the heart rate and the workload on the heart.
3. **Diuretics** (e.g., furosemide): to reduce fluid buildup in the body.
4. **Aldosterone antagonists** (e.g., spironolactone): to prevent salt retention and reduce strain on the heart.
5. **Digoxin**: to help the heart beat more strongly and regularly.
6. **Anticoagulants** (e.g., warfarin): to prevent blood clots, especially if there is a risk of arrhythmias.

Management might also involve lifestyle changes, such as dietary adjustments, regular exercise as recommended, and monitoring fluid intake.
Repurposable Drugs: Dilated Cardiomyopathy 1BB (DCM 1BB) is a genetic form of dilated cardiomyopathy, a condition characterized by an enlarged and weakened left ventricle. While specific treatments for DCM 1BB are continually being researched, several drugs initially developed for other conditions have been repurposed to help manage symptoms and improve outcomes in patients with dilated cardiomyopathy. These repurposable drugs include:

1. **Beta-blockers** (e.g., Carvedilol, Metoprolol): These help to improve heart function, reduce symptoms, and decrease the risk of death.
2. **ACE inhibitors** (e.g., Enalapril, Lisinopril): These help relax blood vessels, lower blood pressure, and reduce the workload on the heart.
3. **Angiotensin II receptor blockers (ARBs)** (e.g., Losartan, Valsartan): Often used in patients who cannot tolerate ACE inhibitors.
4. **Aldosterone antagonists** (e.g., Spironolactone, Eplerenone): These help to reduce fluid buildup and decrease the stress on the heart.
5. **Diuretics** (e.g., Furosemide): These help manage fluid retention associated with heart failure.

Patients with DCM 1BB should work closely with their healthcare providers to develop an individualized treatment plan.
Metabolites: Dilated cardiomyopathy (DCM) is a condition characterized by the enlargement and impaired contraction of the heart's ventricles. Since you have referred to "dilated_cardiomyopathy_1bb," which could imply a specific type or genetic variant of DCM, it's essential to understand that metabolomic changes in DCM broadly include alterations in energy metabolism, oxidative stress markers, and mitochondrial function. Key metabolites involved may include:

1. **Glucose Metabolites**: Reduced glucose oxidation and increased glycolysis byproducts.
2. **Fatty Acid Metabolites**: Lower levels of fatty acid oxidation intermediates, indicating impaired fatty acid metabolism.
3. **Amino Acid Metabolites**: Increased levels of certain amino acids such as lysine and branched-chain amino acids, possibly reflecting altered protein metabolism.
4. **Lactate**: Elevated lactate levels, indicating a shift towards anaerobic metabolism due to inefficient mitochondria.
5. **Acylcarnitines**: These can be increased, reflecting disturbances in fatty acid oxidation and transport.

Metabolomics in DCM studies can reveal abnormalities in these and other metabolic pathways, contributing to the understanding of disease mechanisms and potential therapeutic targets.
Nutraceuticals: For dilated cardiomyopathy (DCM), there is no specific nutraceutical listed for "1bb" as it may refer to a subtype in research settings. However, general nutraceutical approaches for DCM include:

1. **Coenzyme Q10 (CoQ10)**: Known for its role in energy production and antioxidant properties, which may help improve heart function.

2. **L-carnitine**: An amino acid derivative that aids in fatty acid metabolism, potentially beneficial for heart muscle energy production.

3. **Taurine**: Another amino acid that supports heart function and cardiovascular health.

4. **Omega-3 fatty acids**: Found in fish oil, these can help reduce inflammation and improve heart health.

5. **Magnesium and potassium**: Essential minerals that are vital for proper cardiac function.

Note: Always consult a healthcare provider before starting any new supplements, as interactions with other medications or conditions need to be considered.
Peptides: Dilated cardiomyopathy 1BB (DCM1BB) is a genetic form of dilated cardiomyopathy caused by mutations in the genes encoding the cardiac-specific isoform of the RNA-binding motif protein 20 (RBM20). Peptides related to DCM1BB, such as derived fragments of RBM20 or those used in research to study its function, can be utilized in experimental settings to understand better the disease mechanisms and potentially develop therapeutic strategies. Currently, specific peptide-based therapies for DCM1BB are not clinically established.

"Nan" does not provide sufficient context to infer its meaning in relation to DCM1BB. If it refers to nanotechnology or nanoscale materials, it could be relevant in advanced research contexts, such as developing targeted drug delivery systems or novel diagnostic tools, but specific applications for DCM1BB using nanotechnology are not well-defined or clinically available at this stage.